Details
Title
A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity
Author
Burgoyne, Adam M 1 ; Vann, Kendra R 2 ; Joshi Shweta 3 ; Morales, Guillermo A 4 ; Vega, Francisco M 5
; Singh, Alok 3 ; Pal Dhananjaya 3 ; Merati, Aran B 1 ; Kutateladze, Tatiana G 2
; Durden, Donald L 6
1 University of California San Diego, Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
2 University of Colorado School of Medicine, Department of Pharmacology, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)
3 University of California San Diego, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
4 SignalRx Pharmaceuticals, San Diego, USA (GRID:grid.505298.3)
5 University of California San Diego, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Universidad de Sevilla, Department of Cell Biology, Instituto de Biomedicina de Sevilla, Sevilla, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229)
6 University of California San Diego, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); SignalRx Pharmaceuticals, San Diego, USA (GRID:grid.505298.3)
; Singh, Alok 3 ; Pal Dhananjaya 3 ; Merati, Aran B 1 ; Kutateladze, Tatiana G 2
; Durden, Donald L 6 1 University of California San Diego, Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
2 University of Colorado School of Medicine, Department of Pharmacology, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)
3 University of California San Diego, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
4 SignalRx Pharmaceuticals, San Diego, USA (GRID:grid.505298.3)
5 University of California San Diego, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Universidad de Sevilla, Department of Cell Biology, Instituto de Biomedicina de Sevilla, Sevilla, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229)
6 University of California San Diego, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); SignalRx Pharmaceuticals, San Diego, USA (GRID:grid.505298.3)
Publication year
2020
Publication date
2020
e-ISSN
20565968
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2427391589
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.